Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81215752 | 8121575 | 2 | F | 20080715 | 20121009 | 20110906 | 20121029 | EXP | US-GLAXOSMITHKLINE-A0797819A | GLAXOSMITHKLINE | 49.99 | YR | M | Y | 115.90000 | KG | 20121029 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81215752 | 8121575 | 1 | PS | ROSIGLITAZONE MALEATE | 1 | ORAL | D | 21071 | Tablet | ||||||||||
| 81215752 | 8121575 | 2 | SS | Avandamet | 1 | ORAL | D | 21410 | Tablet | ||||||||||
| 81215752 | 8121575 | 3 | C | Tenoretic | 1 | D | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 81215752 | 8121575 | 1 | Type 2 diabetes mellitus |
| 81215752 | 8121575 | 2 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 81215752 | 8121575 | DE |
| 81215752 | 8121575 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 81215752 | 8121575 | Coronary artery disease | |
| 81215752 | 8121575 | Death | |
| 81215752 | 8121575 | Myocardial infarction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 81215752 | 8121575 | 1 | 20080721 | 0 | ||
| 81215752 | 8121575 | 2 | 200408 | 200807 | 0 |